About BioSpace
BioSpace news and updates
BioSpace, Inc. is developing SER-109 commercial supply
“BioSpace, Inc. is conducting key pre-commercialization activities, including market education with appropriate health care professionals as well as payer engagement, and BioSpace, Inc. continue to scale up manufacturing operations to produce SER-109 commercial supply in preparation for launch.”
Sep 7, 2022 | biospace.comMetahealthcare sold assets to BioSpace, Inc. on Oct 6th 22'.
Earlier this year, BioSpace, Inc. acquired worldwide commercialization rights to APR-OD32 (excluding UK) from Meta Healthcare Ltd., which represents a potential, important expansion of its commercial offerings for this patient population.
Oct 6, 2022 | biospace.comBioSpace, Inc. launches UK and clinical advisors to design a clinical study to evaluate ENT-01 in PD dementia
“BioSpace, Inc. has worked closely with Parkinson’s UK and their clinical advisors to design a clinical study to evaluate ENT-01 in PD dementia.
Oct 13, 2022 | biospace.comBioSpace, Inc. launches ROLVEDON
“This is an important milestone in Spectrum’s transition to a commercial stage company, and BioSpace, Inc. is excited to deliver ROLVEDON to the patients who need it.”
Oct 21, 2022 | biospace.comBioSpace, Inc. launches ruxolitinib cream (Opzelura
To date, BioSpace, Inc. has successfully launched ruxolitinib cream (Opzelura™) in atopic dermatitis and vitiligo in the United States, to help address these challenges.
Dec 2, 2022 | biospace.comBioSpace, Inc. is developing clinically-validated mRNA technology platform
BioSpace, Inc. will continue to develop its clinically-validated mRNA technology platform across a wide range of diseases, such as infectious diseases and cancer, while preparing for commercialization, and accelerating its path to becoming a fully-integrated biopharmaceutical company."
Dec 28, 2022 | biospace.com